NCT05543681: An ongoing trial by IGC Pharma LLC
This trial is ongoing. It must report results 11 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05543681 |
|---|---|
| Title | A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants With Dementia Due to Alzheimer's Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 11, 2022 |
| Completion date | March 30, 2026 |
| Required reporting date | March 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |